April 30, 2014Open Access
View Full PaperOverall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib
Key Points
Key points are not available for this paper at this time.
Abstract
Survival results are now mature for a noninferiority trial comparing pazopanib with sunitinib in renal-cell carcinoma. Median survival was 42.5 months with pazopanib and 43.6 months with sunitinib, a difference that wasnot significant.